Work

Mesenchymal stem cells promote erlotinib resistance in non-small cell lung cancer through the HGF-AKT/ERK1/2-OPN pathway

Year: 2025

Type: article

Abstract: OBJECTIVES: To investigate the mechanisms by which mesenchymal stem cells (MSCs) contribute to erlotinib resistance in non-small cell lung cancer (NSCLC). METHODS: validation, a xenograft model was established by co-injecting HCC827 cells and MSCs into NOD/SCID mice. RESULTS: , tumors derived from co-injected MSCs and HCC827 cells exhibited significantly greater volume and weight after erlotinib treatment compared to control tumors. CONCLUSIONS: This study identifies a novel MSC-mediated resistance mechanism in which MSC-derived HGF activates compensatory AKT/ERK1/2 signaling, circumventing EGFR blockade by erlotinib. Concurrent upregulation of OPN in NSCLC cells forms a synergistic survival axis under erlotinib pressure. These findings suggest that targeting MSC-derived HGF and tumor-derived OPN may offer promising strategies to overcome erlotinib resistance in NSCLC.

Source: American Journal of Translational Research

DOI: 10.62347/rkyl8675

Author: Yue Yang

Institutions: Northwest Minzu University, State Ethnic Affairs Commission, Lanzhou University

Language: English

Topic: Lung Cancer Treatments and Mutations

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: green

OpenAlex ID: W4412775783

FWCI: 1.215

Cites: 44

Cited by: 2

Related to: 10